Literature DB >> 9292017

Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses.

F X Berthet1, H G Zeller, M T Drouet, J Rauzier, J P Digoutte, V Deubel.   

Abstract

We compared the sequence of an envelope protein gene fragment from 21 temporally distinct West Nile (WN) virus strains, isolated in nine African countries and in France. Alignment of nucleotide sequences defined two groups of viruses which diverged by up to 29%. The first group of subtypes is composed of nine WN strains from France and Africa. The Austral-Asian Kunjin virus was classified as a WN subtype in this first group. The second group includes 12 WN strains from Africa and Madagascar. Four strains harboured a 12 nucleotide in-frame deletion. The loss of the corresponding four amino acids resulted in the loss of the potential glycosylation site present in several WN strains. The distribution of virus subtypes into two lineages did not correlate with host preference or geographical origin. The isolation of closely related subtypes in distant countries is consistent with WN viruses being disseminated by migrating birds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292017     DOI: 10.1099/0022-1317-78-9-2293

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  74 in total

1.  A phylogenetic approach to following West Nile virus in Connecticut.

Authors:  J F Anderson; C R Vossbrinck; T G Andreadis; A Iton; W H Beckwith; D R Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

2.  Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens.

Authors:  Diana Ludolfs; Stefan Schilling; Jan Altenschmidt; Herbert Schmitz
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence.

Authors:  Brian C Keller; Brenda L Fredericksen; Melanie A Samuel; Richard E Mock; Peter W Mason; Michael S Diamond; Michael Gale
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection.

Authors:  Olivia Perwitasari; Hyelim Cho; Michael S Diamond; Michael Gale
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

5.  Comparison of flavivirus universal primer pairs and development of a rapid, highly sensitive heminested reverse transcription-PCR assay for detection of flaviviruses targeted to a conserved region of the NS5 gene sequences.

Authors:  N Scaramozzino; J M Crance; A Jouan; D A DeBriel; F Stoll; D Garin
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Requirement of glycosylation of West Nile virus envelope protein for infection of, but not spread within, Culex quinquefasciatus mosquito vectors.

Authors:  Robin M Moudy; Anne F Payne; Brittany L Dodson; Laura D Kramer
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

7.  West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.

Authors:  Carl W Davis; Hai-Yen Nguyen; Sheri L Hanna; Melissa D Sánchez; Robert W Doms; Theodore C Pierson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling.

Authors:  Jared D Evans; Christoph Seeger
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 9.  West Nile virus infection and immunity.

Authors:  Mehul S Suthar; Michael S Diamond; Michael Gale
Journal:  Nat Rev Microbiol       Date:  2013-02       Impact factor: 60.633

10.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.